Generic drug: idarubicin hydrochloride

Brand name: Idamycin PFS

What is Idamycin PFS (idarubicin hydrochloride), and how does it work?

Idamycin PFS Injection (idarubicin hydrochloride) is a cancer (antineoplastic) medication used to treat a type of blood cancer (acute myeloid leukemia -AML) in adults. Idamycin PFS is available in generic form.

What are the side effects of Idamycin PFS?

WARNING

  1. Idamycin PFS Injection should be given slowly into a freely flowing intravenous infusion. It must never be given intramuscularly or subcutaneously. Severe local tissue necrosis can occur if there is extravasation during administration.
  2. As is the case with other anthracyclines the use of Idamycin PFS can cause myocardial toxicity leading to congestive heart failure. Cardiac toxicity is more common in patients who have received prior anthracyclines or who have pre-existing cardiac disease.
  3. As is usual with antileukemic agents, severe myelosuppression occurs when Idamycin PFS is used at effective therapeutic doses.
  4. It is recommended that Idamycin PFS be administered only under the supervision of a physician who is experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection.
  5. Dosage should be reduced in patients with impaired hepatic or renal function.

Common side effects of Idamycin PFS include:

Temporary hair loss is a common side effect of Idamycin PFS. Normal hair growth should return after treatment with Idamycin PFS has ended.

What is the dosage for Idamycin PFS?

For induction therapy in adult patients with AML the following dose schedule is recommended:

  • Idamycin PFS Injection 12 mg/m2 daily for 3 days by slow (10 to 15 min) intravenous injection in combination with cytarabine.
  • The cytarabine may be given as 100 mg/m2 daily by continuous infusion for 7 days or as cytarabine 25 mg/m2 intravenous bolus followed by cytarabine 200 mg/m2 daily for 5 days continuous infusion.
  • In patients with unequivocal evidence of leukemia after the first induction course, a second course may be administered.
  • Administration of the second course should be delayed in patients who experience severe mucositis, until recovery from this toxicity has occurred, and a dose reduction of 25% is recommended.
  • In patients with hepatic and/or renal impairment, a dose reduction of Idamycin PFS should be considered. Idamycin PFS should not be administered if the bilirubin level exceeds 5 mg%.
  • The benefit of consolidation in prolonging the duration of remissions and survival is not proven. There is no consensus regarding optional regimens to be used for consolidation.

What drugs interact with Idamycin PFS?

No information provided

Is Idamycin PFS safe to use while pregnant or breastfeeding?

  • There are no adequate and well-controlled studies in pregnant women. If idarubicin is to be used during pregnancy, or if the patient becomes pregnant during therapy, the patient should be apprised of the potential hazard to the fetus.
  • Women of childbearing potential should be advised to avoid pregnancy. It is not known whether this drug is excreted in human milk.
  • Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from idarubicin, mothers should discontinue nursing prior to taking this drug.

SLIDESHOW

Cancer: Symptoms of Common Cancers in Men See Slideshow

Treatment & Diagnosis

Medications & Supplements

Health Solutions From Our Sponsors

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Medically Reviewed on 4/7/2021
References
All sections courtesy of the U.S. Food and Drug Administration